Provided by Tiger Trade Technology Pte. Ltd.

ASCENTAGE-B

47.800
+1.5003.24%
Volume:1.24M
Turnover:58.61M
Market Cap:17.83B
PE:-35.61
High:48.300
Open:46.300
Low:45.740
Close:46.300
52wk High:95.350
52wk Low:31.350
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:2.15
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.342
ROE:-159.65%
ROA:-22.77%
PB:23.65
PE(LYR):-35.61
PS:40.33

Loading ...

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Reuters
·
Yesterday

Ascentage Pharma Announces Ind Clearance by the China Cde for Btk Degrader Apg-3288

THOMSON REUTERS
·
Feb 06

China erteilt Ascentage Pharma IND-Genehmigung für BTK-Degrader APG-3288

Reuters
·
Feb 06

Ascentage Pharma (06855) Announces January 2026 Monthly Return

Bulletin Express
·
Feb 05

ASCENTAGE-B Stock Surges Over 3% in Intraday Trading as BTK Degrader Class 1 New Drug APG-3288 Tablets Gain Clinical Approval

Deep News
·
Feb 04

Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

Reuters
·
Jan 15

A Look At Ascentage Pharma Group International's Valuation After FDA IND Clearance For APG-3288

Simply Wall St.
·
Jan 10

Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance

Stock News
·
Jan 07

FDA Clears IND for Ascentage Pharma’s BTK Degrader APG-3288

Reuters
·
Jan 07

Ascentage Pharma Announces Ind Clearance by the U.S. Food and Drug Administration for Btk Degrader Apg-3288

THOMSON REUTERS
·
Jan 07

ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director

Stock News
·
Dec 30, 2025

Ascentage Pharma Group International Files Director List to HKEX

Reuters
·
Dec 30, 2025

Ascentage Pharma Appoints Dr. Debra Yu to Nomination Committee and Dr. David Sidransky as Lead Independent Director

Reuters
·
Dec 30, 2025

Assessing Ascentage Pharma (SEHK:6855) Valuation After New ASH 2025 Hematology Data on Olverembatinib and Lisaftoclax

Simply Wall St.
·
Dec 21, 2025

Ascentage Pharma to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 17, 2025

CICC Maintains "Outperform" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU

Stock News
·
Dec 17, 2025

Is Ascentage Pharma Group International Pricing In Too Much Biotech Optimism After Big 3 Year Rally?

Simply Wall St.
·
Dec 14, 2025

Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025

Reuters
·
Dec 09, 2025

Ascentage Pharma Reports Strong Phase II Results for Lisaftoclax in BTK-Refractory CLL/SLL

Reuters
·
Dec 08, 2025

Revisiting Ascentage Pharma Group International (SEHK:6855)’s Valuation After Its Strong One-Year Share Price Gain

Simply Wall St.
·
Dec 07, 2025